Advertisement.
Advertisement.
Advertisement
Advertisement.
NKTR Nektar Therapeutics
7,024
| Market Cap | $252.11M |
| Volume | 912,287.00 |
| 52-Wk High | $1.93 |
| 52-Wk Low | $0.4126 |
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
PR Newswire•1 month ago
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 Nektar Therapeutics Presents First...
Share to Feed
Nektar Management to Present at Upcoming Investor Conferences Nektar Management to Present at Upcoming Investor Conferences PR Newswire SAN FRANCISCO, May 30, 2024 SAN FRANCISCO, May 30, 2024...
PR Newswire•2 months ago
Nektar Therapeutics Reports First Quarter 2024 Financial Results Nektar Therapeutics Reports First Quarter 2024 Financial Results PR Newswire SAN FRANCISCO, May 9, 2024 SAN FRANCISCO, May 9, 2024...
PR Newswire•3 months ago
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets Nektar to Announce Financial Results for the First Quarter 2024...
PR Newswire•3 months ago
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune...
PR Newswire•4 months ago
GSA Capital Partners LLP lifted its position in shares of Nektar Therapeutics (NASDAQ:NKTR Free Report) by 931.5% during the 3rd quarter, according to its most recent disclosure with the SEC...
Ticker Report•5 months ago
Nektar Therapeutics (NASDAQ:NKTR Free Report) had its price target increased by Jefferies Financial Group from $0.50 to $1.00 in a report published on Wednesday, Benzinga reports. Jefferies...
Ticker Report•5 months ago
Nektar Therapeutics (NASDAQ:NKTR Free Report) Equities research analysts at William Blair lowered their Q1 2024 earnings estimates for shares of Nektar Therapeutics in a report...
Zolmax•5 months ago
Shares of Nektar Therapeutics (NASDAQ:NKTR Get Free Report) have been assigned an average recommendation of Hold from the five ratings firms that are presently covering the...
Zolmax•5 months ago
Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript...
SeekingAlpha•5 months ago